Please Wait
Applying Filters...
menu
    • menu
    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Lenacapavir Sodium

    DEVELOPMENTS

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Gs-hiv sodium, Bdt58wj9we, 2283356-12-5, Unii-bdt58wj9we, Gs-6207-02, Sunlenca
    Molecular Formula
    C39H31ClF10N7NaO5S2
    Molecular Weight
    990.3  g/mol
    InChI Key
    SSXPGMNGIORJAQ-PZNXWHLTSA-M
    FDA UNII
    BDT58WJ9WE
    LENACAPAVIR SODIUM is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for hiv-1 infection and hiv infection.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    sodium [4-chloro-7-[2-[(1S)-2-(3,5-difluorophenyl)-1-[[2-[(2S,4R)-5,5-difluoro-9-(trifluoromethyl)-7,8-diazatricyclo[4.3.0.02,4]nona-1(6),8-dien-7-yl]acetyl]amino]ethyl]-6-(3-methyl-3-methylsulfonylbut-1-ynyl)-3-pyridinyl]-1-(2,2,2-trifluoroethyl)indazol-3-yl]-methylsulfonylazanide
    2.1.2 InChI
    InChI=1S/C39H32ClF10N7O5S2.Na/c1-36(2,63(3,59)60)10-9-21-5-6-22(23-7-8-26(40)30-32(23)57(17-37(43,44)45)54-35(30)55-64(4,61)62)31(51-21)27(13-18-11-19(41)14-20(42)12-18)52-28(58)16-56-34-29(33(53-56)39(48,49)50)24-15-25(24)38(34,46)47;/h5-8,11-12,14,24-25,27H,13,15-17H2,1-4H3,(H2,52,54,55,58);/q;+1/p-1/t24-,25+,27-;/m0./s1
    2.1.3 InChI Key
    SSXPGMNGIORJAQ-PZNXWHLTSA-M
    2.2 Other Identifiers
    2.2.1 UNII
    BDT58WJ9WE
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. Gs-hiv Sodium

    2. Bdt58wj9we

    3. 2283356-12-5

    4. Unii-bdt58wj9we

    5. Gs-6207-02

    6. Sunlenca

    7. 1h-cyclopropa(3,4)cyclopenta(1,2-c)pyrazole-1-acetamide, N-((1s)-1-(3-(4-chloro-3-((methylsulfonyl)amino)-1-(2,2,2-trifluoroethyl)-1h-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)-1-butyn-1-yl)-2-pyridinyl)-2-(3,5-difluorophenyl)ethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-3-(trifluoromethyl)-, Sodium Salt (1:1), (3bs,4ar)-

    8. N-((1s)-1-(3-(4-chloro-3-(methanesulfonamido)-1-(2,2,2-trifluoroethyl)-1h-indazol-7-yl)-6-(3-(methanesulfonyl)-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bs,4ar)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro1h-cyclopropa(3,4)cyclopenta(1,2-c)pyrazol-1-yl)acetamide, Sodium Salt (1:1)

    9. Refchem:58517

    10. Gs-hiv Na

    11. Lenacapavir Sodium [usan]

    12. Yeztugo

    13. Sunlenca (tn)

    14. Lenacapavir (sodium)

    15. Lenacapavir Sodium [who-dd]

    16. Orb2814823

    17. Chembl4802249

    18. Lenacapavir Sodium (jan/usan)

    19. Schembl30612482

    20. Schembl30685531

    21. Ex-a5518a

    22. Hy-111964a

    23. D12162

    2.4 Create Date
    2020-08-13
    3 Chemical and Physical Properties
    Molecular Weight 990.3 g/mol
    Molecular Formula C39H31ClF10N7NaO5S2
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count19
    Rotatable Bond Count13
    Exact Mass Da
    Monoisotopic Mass Da
    Topological Polar Surface Area164
    Heavy Atom Count65
    Formal Charge0
    Complexity2050
    Isotope Atom Count0
    Defined Atom Stereocenter Count3
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Indication

    Sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant HIV 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4. 2 and 5. 1). Sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant HIV 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4. 2 and 5. 1).

    5 Pharmacology and Biochemistry
    5.1 FDA Pharmacological Classification
    5.1.1 Pharmacological Classes
    Breast Cancer Resistance Protein Inhibitors [MoA]; HIV Capsid Inhibitors [MoA]; Cytochrome P450 3A Inhibitors [MoA]; P-Glycoprotein Inhibitors [MoA]; Human Immunodeficiency Virus 1 Capsid Inhibitor [EPC]
    5.2 ATC Code

    J05AX